OCREVUS 300MG/10ML VIAL I.V. INF

OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis. OCREVUS is administered twice yearly as a 600 mg IV infusion. The initial 600 mg dose is administered as 2 separate intravenous infusions given over approximiately 2.5 hours: first as a 300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion Subsequent doses thereafter administered over approximately 3.5 hours as a single 600 mg intravenous infusion every 6 months (24 weeks)